Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDAH1 | O94760 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.43 |
| ▸ | HPGD | P15428 | 7/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3102505 | 0.82 | KDM4E (0.50) | ALDH1A1MAOBKDM4ECYP1A2LMNA | |
| SCHEMBL3101569 | 0.82 | ESR1 (0.56) | ALDH1A1HPGDMAPTMAOBMAOA | |
| SCHEMBL3099337 | 0.82 | ERN1 (0.44) | ALDH1A1HPGDCYP3A4MEN1KMT2A | |
| SCHEMBL3100220 | 0.82 | NPC1 (0.55) | ALDH1A1HPGDKDM4ETDP1CYP1A2 | |
| SCHEMBL3104507 | 0.82 | SLC9A1 (0.48) | ALDH1A1HPGDMAPTSLC9A1MEN1 | |
| SCHEMBL3089847 | 0.82 | GABRP (0.46) | SLC9A1GAACYP1A2GABRPGABRD | |
| SCHEMBL3106747 | 0.81 | EGFR (0.57) | ALDH1A1HPGDMAPTMAOBCYP3A4 | |
| SCHEMBL3091522 | 0.80 | ALDH1A1 (0.52) | ALDH1A1HPGDMAPTMAOBSLC9A1 | |
| SCHEMBL3106911 | 0.80 | CYP3A4 (0.55) | ALDH1A1HPGDCYP3A4MEN1KMT2A | |
| SCHEMBL11762040 | 0.79 | KDM4E (0.50) | DDAH1ALDH1A1HPGDMAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2210876-B1 | HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST | TAKEDA PHARMACEUTICAL (JP) | 2015-05-20 | — | — | EP | disclosed |
| US-8309580-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20110054017-A1 | SUBSTITUTED FURANS AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| US-20110054017-A1 | SUBSTITUTED FURANS AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| US-20110054017-A1 | SUBSTITUTED FURANS AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| EP-2240461-A1 | SUBSTITUTED FURANS AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-10-20 | — | — | EP | disclosed |
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2210876-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009097991-A1 | SUBSTITUTED FURANS AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009097991-A1 | SUBSTITUTED FURANS AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-08-13 | — | — | WO | disclosed |
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MARZABADI MOHAMMAD R | 2007-02-22 | — | — | US | disclosed |
| US-7067534-B1 | Substituted anilinic piperidines as MCH selective antagonists | H. LUNDBECK A/S (DK) | 2006-06-27 | — | — | US | disclosed |
| EP-1411942-A4 | SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS | SYNAPTIC PHARMA CORP (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-1411942-A1 | SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS | Synaptic Pharmaceutical Corporation (US) | 2004-04-28 | — | — | EP | disclosed |
| US-6727264-B1 | MELANIN CONCENTRATING HORMONE-1 RECEPTOR ANTAGONISTS; SLEEP, EATING, SEXUAL DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-27 | — | — | US | disclosed |
| WO-2003004027-A1 | SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MCHR1, MCHR2, MC1R | DDAH1 720/4885ALDH1A1 620/4885HPGD 2602/4885 |
| US-20110054017-A1 | SUBSTITUTED FURANS AND THEIR USE | XDH, TXN2, FABP3 | DDAH1 1153/4885ALDH1A1 424/4885HPGD 134/4885 |
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | GLP1R, GPR119, GCGR | DDAH1 1103/4885ALDH1A1 3963/4885HPGD 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.